This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
AstraZeneca (AZN.LN) – Said its asthma treatment drug tralokinumab didn't meet its primary endpoint in a clinical trial and didn't demonstrate a significant reduction in the annual rate of asthma attacks in the first of two Phase III clinical trials. The results of the second trial are expected in H2 of 2017. Closing price 4710.50p (Dow Jones Newswires)
Barratt Developments (BDEV.L) – Expects profit would reach up to £733m, at the top end of analysts' expectations, over 7% higher y-o-y. Expected 2016/17 pre-tax profit to meet the top end of market expectations despite building only around 30 more homes y-o-y to reach a total of 17,350 units. Closing price 596.50p (Bloomberg)
Compass Group (CPG.L) - Has seen H1 underlying operating profit of £894m, marginally beating estimates of £893m, as well as interim dividend beating expectations. The company also proposed a special dividend of 61pp share. Outlook is set to meet expectations for 2017 with growth weighted to H2. Closing price 1595.00p (Bloomberg)
ITV (ITV.L) - Saw Q1 total revenue fall 3% to £731m with broadcasting revenue also down 6% and expects net advertising revenue to be down 8%-9% for the years H1. Their CEO is to step down due to a slowdown after Brexit hit advertising. Closing price 200.80p (Bloomberg)
Talk Talk Telecom Group (TALK.L) - Cut its final dividend by 35% to 10.29pp share annually, from 15.87p previously, reporting a revenue drop of 3% to £1.78bn against estimates of £1.8bn. Earnings before tax also came in light at £304m versus £309m expected losing 49,000 customer accounts. Closing price 182.50p (Bloomberg)
For more information on any of these individual news items, call into the trading floor
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research